KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Preferred Stock Liabilities (2018 - 2019)

Adaptive Biotechnologies' Preferred Stock Liabilities history spans 2 years, with the latest figure at $561.9 million for Q2 2019.

  • For Q2 2019, Preferred Stock Liabilities changed 0.23% year-over-year to $561.9 million; the TTM value through Jun 2019 reached $561.9 million, changed 0.23%, while the annual FY2018 figure was $560.9 million, 0.08% changed from the prior year.
  • Preferred Stock Liabilities for Q2 2019 was $561.9 million at Adaptive Biotechnologies, roughly flat from $561.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $561.9 million in Q2 2019 and bottomed at $560.7 million in Q2 2018.